Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Holmdahl

Daniel Patrick Holmdahl, Roseville, MN US

Patent application numberDescriptionPublished
20090156909System For Contextual Display of Data From an Implantable Medical Device - Embodiments of the invention are related to data management systems, amongst other things. In an embodiment, the invention includes a video output and a processor in communication with the video output, wherein the video output and the processor are configured to display information regarding a patient in a first format and a second format through the video output simultaneously, the first format comprising a graphical formal and the second format comprising a textual format, the information displayed in the first format divided into a plurality of phases, wherein the system is configured to automatically change the information displayed in the second format based on user selection of one of the plurality of phases. Other embodiments are also included herein.06-18-2009

Henrik Carl Holmdahl, San Francisco, CA US

Patent application numberDescriptionPublished
20080218517SYSTEM AND METHOD FOR CALCULATING MULTI-RESOLUTION DYNAMIC AMBIENT OCCLUSION - A system and method for generating a three-dimensional image is provided. An embodiment of the present invention includes calculating the ambient occlusion at a vertex in multiple, independent stages. Determining the global AO at the vertex may be performed using a first technique. Determining the local AO at the vertex may be performed using a second technique. The total AO can be found as a function of the local AO and global AO.09-11-2008

Rikard Holmdahl, Lund SE

Patent application numberDescriptionPublished
20080227135Autoimmune Conditions and NADPH Oxidase Defects - The invention relates to methods and materials involved in diagnosing and treating autoimmune conditions. In particular, the invention relates to methods and materials involved in diagnosing arthritis conditions that are accompanied by an NADPH oxidase deficiency, methods and materials involved in treating, preventing, or delaying the onset of arthritis conditions that are accompanied by an NADPH oxidase deficiency, and methods and materials involved in identifying agonists and antagonists of NADPH oxidase activity.09-18-2008
20080262197METHODS AND MATERIALS FOR TREATING INFLAMMATORY CONDITIONS - The invention provides methods and materials for treating inflammatory conditions. Specifically, the invention provides polypeptides, isolated nucleic acids, host cells, and methods that can be used to induce an antibody response in a mammal against an antigen such as C5 or C5a. For example, the methods and materials described herein can be used to reduce the effects of C5a within a mammal by reducing the amount of total and receptor bound C5a in the mammal.10-23-2008
20100135981USE OF THE ENDOGLYCOSIDASE ENDOS FOR TREATING IMMUNOGLOBULIN G MEDIATED DISEASES - The invention provides use of an EndoS polypeptide, or a polynucleotide encoding an EndoS polypeptide, in the manufacture of a medicament for the treatment or prevention of a disease or condition mediated by IgG antibodies.06-03-2010
20100227354Autoimmune Conditions and NADPH Oxidase Defects - The invention relates to methods and materials involved in diagnosing and treating autoimmune conditions. In particular, the invention relates to methods and materials involved in diagnosing arthritis conditions that are accompanied by an NADPH oxidase deficiency, methods and materials involved in treating, preventing, or delaying the onset of arthritis conditions that are accompanied by an NADPH oxidase deficiency, and methods and materials involved in identifying agonists and antagonists of NADPH oxidase activity.09-09-2010
20100303781Treatment - The invention provides use of an IdeS polypeptide, or a polynucleotide encoding an IdeS polypeptide, in the manufacture of a medicament for the treatment or prevention of a disease or condition mediated by IgG antibodies.12-02-2010
20110015278PHYTOL AS A CHOLESTEROL LOWERING AGENT - Phytol (3,7,11,15-Tetramethyl-2-hexadecen-1-ol), or derivates thereof, of natural or synthetic origin are used as active ingredient in formulations to lower serum levels of triglycerides and/or cholesterol. Phytol can be administered to patients with disease conditions related to increased levels of cholesterol or triglycerides such as type II diabetes, obesity or other patients in risk of cardiovascular diseases due to elevated cholesterol levels. Phytol can also be administered to healthy individuals to maintain normal levels of serum cholesterol.01-20-2011
20110200993NEW TREATMENT OF AUTOIMMUNE CONDITIONS - The invention relates to methods and materials involved in diagnosing and treating autoimmune conditions. In particular, the invention relates to methods and materials involved in identifying agent suitable for the prophylaxis, prevention and/or treatment of an autoimmune condition. The invention further relates to methods and materials involved in diagnosing autoimmune diseases like arthritis, multiple sclerosis and inflammatory bowels disease accompanied by decreased cellular uptake of amino acids caused by defects in cellular amino acid transporters like Slc38A1 (Solute carrier family 38, member 1). The invention also relates to methods and materials involved in diagnosing, treating, preventing, or delaying the onset and ameliorating the symptoms of autoimmune conditions that are accompanied by defects in cellular amino acid transporters.08-18-2011

Patent applications by Rikard Holmdahl, Lund SE

Rikard Holmdahl, Stockholm SE

Patent application numberDescriptionPublished
20110318340DEGLYCOSYLATED ANTIBODIES - The present invention provides an antibody, or antibody fragment, with modified glycosylation for use in treating or preventing a disease or condition, where the antibody or fragment: (a) suppresses an inflammatory condition forming part of the disease or condition to be treated or prevented; and/or (b) displays increased efficacy and/or decreased side effects in comparision to treatment or prevention with the corresponding antibody with unmodified glycosylation.12-29-2011